Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys
- 1 January 2003
- Vol. 32 (1) , 45-55
- https://doi.org/10.1016/s8756-3282(02)00923-7
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- The New Bisphosphonate Ibandronate in the Treatment of Tumor-Induced HypercalcemiaOncology Research and Treatment, 1999
- Zoledronate Prevents the Development of Absolute Osteopenia Following Ovariectomy in Adult Rhesus MonkeysJournal of Bone and Mineral Research, 1998
- The androgenic anabolic steroid nandrolone decanoate prevents osteopenia and inhibits bone turnover in ovariectomized cynomolgus monkeysBone, 1997
- Decreased Bone Mass and Strength in Ovariectomized Cynomolgus Monkeys (Macaca fascicularis)Calcified Tissue International, 1997
- Bisphosphonates: Preclinical Aspects and Use in OsteoporosisAnnals of Medicine, 1997
- Ibandronate in Malignant Bone Diseases and Osteoporosis – Preclinical ResultsOncology Research and Treatment, 1997
- Esophagitis Associated with the Use of AlendronateNew England Journal of Medicine, 1996
- Bone mass in female cynomolgus macaques: A cross-sectional and longitudinal study by ageCalcified Tissue International, 1994
- The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates.Journal of Clinical Investigation, 1993
- Consensus development conference: Diagnosis, prophylaxis, and treatment of osteoporosisThe American Journal of Medicine, 1993